ARCHIVES

Cancer Drugs Initiatives To Shorten approval Times, Ensure Post-Marketing Studies, FDA Official Says

This article is from The Cancer Letter archive.

Vol. 22 No. 17 | April 26, 1996

Download PDF Visit The Full Archive

Related Articles

Study: Delaying ADT Until Symptoms Appear Can Be Safe in Men with a PSA-based Relapse

May 30, 2014

Ibrutinib Demonstrates 71% ORR In Phase Ib/II CLL and SLL Study

July 26, 2013

House Appropriations Committee Approves $1.221 Bil. Budget For NCI In Fiscal 1986; NIH Gets 45.247 Bil.

October 4, 1985

Black Men Face Disparate Cancer Burden; Minority Rates Vary, Klausner Tells House

April 3, 1998

Attempt To Push NCI To Establish Diagnostic Coordinating Group Fails

July 5, 1974

Gonzalez-Angulo Found Guilty in MD Anderson Poisoning Case

September 26, 2014